These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38956402)

  • 1. Reflectance confocal microscopy for plaque psoriasis therapeutic follow-up during an anti-interleukin-17A monoclonal antibody: an observational study.
    Jiang Q; Qu Z; Wang B; Jiang R; Zhou Y; Wan L; Chen L; Hu F
    Sci Rep; 2024 Jul; 14(1):15121. PubMed ID: 38956402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the response to treatment of psoriasis vulgaris with reflectance confocal microscopy.
    Başaran YK; Gürel MS; Erdemir AT; Turan E; Yurt N; Bağci IS
    Skin Res Technol; 2015 Feb; 21(1):18-24. PubMed ID: 24528203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reflectance confocal microscopy for plaque psoriasis therapeutic follow-up during an anti-TNF-α monoclonal antibody: an observational multicenter study.
    Ardigò M; Agozzino M; Longo C; Lallas A; Di Lernia V; Fabiano A; Conti A; Sperduti I; Argenziano G; Berardesca E; Pellacani G
    J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2363-8. PubMed ID: 26299420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reflectance confocal microscopy: an effective tool for monitoring ultraviolet B phototherapy in psoriasis.
    Wolberink EA; van Erp PE; de Boer-van Huizen RT; van de Kerkhof PC; Gerritsen MJ
    Br J Dermatol; 2012 Aug; 167(2):396-403. PubMed ID: 22512282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deep resolution of clinical, cellular and transcriptomic inflammatory markers of psoriasis over 52 weeks of interleukin-17A inhibition by secukinumab.
    Tomalin LE; Kolbinger F; Suprun M; Wharton KA; Hartmann N; Peters T; Glueck A; Milutinovic M; Krueger JG; Suárez-Fariñas M
    Clin Exp Dermatol; 2024 Jul; 49(8):801-809. PubMed ID: 38240024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bimekizumab versus Secukinumab in Plaque Psoriasis.
    Reich K; Warren RB; Lebwohl M; Gooderham M; Strober B; Langley RG; Paul C; De Cuyper D; Vanvoorden V; Madden C; Cioffi C; Peterson L; Blauvelt A
    N Engl J Med; 2021 Jul; 385(2):142-152. PubMed ID: 33891380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concordance between in vivo reflectance confocal microscopy and histology in the evaluation of plaque psoriasis.
    Ardigo M; Cota C; Berardesca E; González S
    J Eur Acad Dermatol Venereol; 2009 Jun; 23(6):660-7. PubMed ID: 19243485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
    Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular features of psoriatic skin: imaging and quantification using in vivo reflectance confocal microscopy.
    Wolberink EA; van Erp PE; Teussink MM; van de Kerkhof PC; Gerritsen MJ
    Cytometry B Clin Cytom; 2011 May; 80(3):141-9. PubMed ID: 21520401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of secukinumab in Taiwanese patients with moderate to severe plaque psoriasis: Subanalysis from ERASURE phase III study.
    Wu NL; Hsu CJ; Sun FJ; Tsai TF
    J Dermatol; 2017 Oct; 44(10):1129-1137. PubMed ID: 28493369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry.
    Papp KA; Gooderham M; Lynde C; Brassard D; Al-Mohammedi F; Prajapati VH; Delorme I; Albrecht L; Haydey R; Alam MS; Beecker J; Siddha S; Maguin M; Farag MS; Vieira A; Rihakova L; Langley RG
    Arch Dermatol Res; 2024 Jun; 316(7):362. PubMed ID: 38850346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study.
    Papp KA; Weinberg MA; Morris A; Reich K
    Lancet; 2021 Apr; 397(10284):1564-1575. PubMed ID: 33894834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.
    Bokor-Billmann T; Schäkel K
    J Dermatolog Treat; 2019 May; 30(3):216-220. PubMed ID: 30051725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psoriasis plaque test with confocal microscopy: evaluation of different microscopic response pathways in NSAID and steroid treated lesions.
    Ardigò M; Agozzino M; Longo C; Conti A; Di Lernia V; Berardesca E; Pellacani G
    Skin Res Technol; 2013 Nov; 19(4):417-23. PubMed ID: 23521429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secukinumab for patients failing previous tumour necrosis factor-α inhibitor therapy: results of a randomized open-label study (SIGNATURE).
    Warren RB; Barker JNWB; Finlay AY; Burden AD; Kirby B; Armendariz Y; Williams R; Hatchard C; Khare S; Griffiths CEM
    Br J Dermatol; 2020 Jul; 183(1):60-70. PubMed ID: 31628677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis.
    Krueger JG; Wharton KA; Schlitt T; Suprun M; Torene RI; Jiang X; Wang CQ; Fuentes-Duculan J; Hartmann N; Peters T; Koroleva I; Hillenbrand R; Letzkus M; Yu X; Li Y; Glueck A; Hasselberg A; Flannery B; Suárez-Fariñas M; Hueber W
    J Allergy Clin Immunol; 2019 Sep; 144(3):750-763. PubMed ID: 31129129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.
    Ohtsuki M; Morita A; Abe M; Takahashi H; Seko N; Karpov A; Shima T; Papavassilis C; Nakagawa H;
    J Dermatol; 2014 Dec; 41(12):1039-46. PubMed ID: 25354738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
    Rich P; Sigurgeirsson B; Thaci D; Ortonne JP; Paul C; Schopf RE; Morita A; Roseau K; Harfst E; Guettner A; Machacek M; Papavassilis C
    Br J Dermatol; 2013 Feb; 168(2):402-11. PubMed ID: 23362969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.